5. The method of claim **1**, wherein the therapeutic treatment is an adjuvant therapy or a therapy affecting onset and/or progression of metastasis.

6. The method of claim **1**, wherein the therapeutic treatment is also suitable for controlling neoplastic cachexia.

7. The method of claim **1**, wherein the therapeutic treatment further comprises administering one or more cytotoxic and/or cytostatic agents selected from the group consisting of BRAF inhibitors, MEK inhibitors, tyrosine kinase inhibitors, and combinations thereof.

8. The method of claim **1**, wherein the melanocortin receptor-4 antagonist is administered as a pharmaceutical composition, said pharmaceutical composition further comprising at least one pharmaceutically acceptable vehicle, excipient, and/or diluent.

9. The method of claim **8**, wherein the pharmaceutical composition is in a pharmaceutical form suitable for being administered via topical, oral, sublingual, buccal, rectal, subcutaneous, intradermic, transcutaneous, intramuscular, intranasal, inhalation, intravenous, intraarterial, intraperitoneal, intrathecal, intracerebroventricular route or via hyperthermic isolated limb perfusion.

10. The method of claim **9**, wherein the pharmaceutical composition is in a pharmaceutical form suitable for being administered to a patient at a daily dose of the melanocortin receptor-4 antagonist comprised between 1 and 100 mg/kg of body weight of the patient.

11. The method of claim **10**, wherein the daily dose of the melanocortin receptor-4 antagonist is of at least 50 mg/kg of body weight of the patient.

12. The method of claim **11**, wherein the daily dose of the melanocortin receptor-4 antagonist is of at least 25 mg/kg of body weight of the patient.

* * * * *